Sandoz operates in the attractive and growing global off-patent medicines market, which benefits from a growing and aging population, higher rates of chronic disease, increasing market adoption as healthcare systems and payors seek to reduce the cost of medicines, and a consistent supply of upcoming loss of exclusivities (LoEs) as patents for originator products expire. Together, these drivers are expected to support long-term growth in volumes that will more than offset anticipated erosion in price.Year founded
Suurstoffi 14, 6343 Rotkreuz – Switzerland
|Date||Trading entity / Person||Association||Trade type||Volume|
|10.11.23||None||Non-Executive member||Buy||CHF 84,583.00|
|10.11.23||None||Non-Executive member||Buy||CHF 72,917.00|
|10.11.23||None||Non-Executive member||Buy||CHF 13,417.00|
|25.10.23||None||Executive member||Buy||CHF 486,590.00|
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.